Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 2
1997 1
1998 1
1999 1
2000 3
2002 1
2003 1
2004 2
2007 2
2008 3
2010 3
2011 1
2012 3
2013 1
2014 2
2015 4
2016 5
2017 7
2018 7
2019 5
2020 8
2021 2
2022 2
2023 4
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group. Molina JM, et al. Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8. Lancet Infect Dis. 2018. PMID: 29229440 Clinical Trial.
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. Molina JM, et al. N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1. N Engl J Med. 2015. PMID: 26624850 Free article. Clinical Trial.
Information et communication sur les risques liés au médicament et son bon usage auprès des professionnels de santé et du public : principe de précaution, gestion du risque, communication pendant et en dehors des situations de crise.
Molimard M, Bernaud C, Lechat P; et les participants à la table ronde N°6 de Giens XXIX :; Bejan-Angoulvant T, Benattia C, Benkritly A, Braunstein D, Cabut S, David N, Fourrier-Réglat A, Gallet B, Gersberg M, Goni S, Jolliet P, Lamarque-Garnier V, Le Jeunne C, Leurs I, Liard F, Malbezin M, Micallef J, Nguon M. Molimard M, et al. Among authors: bernaud c. Therapie. 2014 Jul-Aug;69(4):355-60. doi: 10.2515/therapie/2014044. Therapie. 2014. PMID: 27393228 French. No abstract available.
Surrogate endpoints in randomized cardiovascular clinical trials.
Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Domanski M, et al. Among authors: bernaud c. Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4. Fundam Clin Pharmacol. 2011. PMID: 20698890 Review.
HIV-infected patients aged above 75years.
Bernaud C, Sécher S, Michau C, Perre P, Fialaire P, Vatan R, Raffi F, Allavena C, Hitoto H. Bernaud C, et al. Med Mal Infect. 2020 Feb;50(1):43-48. doi: 10.1016/j.medmal.2019.04.001. Epub 2019 May 11. Med Mal Infect. 2020. PMID: 31088755
Selatogrel and Other P2Y12 Inhibitors' Putative Off-Target Effects.
Valgimigli M, Storey RF, Sinnaeve PR, Riederer MA, Bernaud C, Frenoux JM. Valgimigli M, et al. Among authors: bernaud c. J Cardiovasc Pharmacol. 2022 Feb 1;79(2):153-154. doi: 10.1097/FJC.0000000000001135. J Cardiovasc Pharmacol. 2022. PMID: 34475343 No abstract available.
La valeur ajoutée relative : quels outils pour l'évaluer ?
Jeunne CL, Woronoff-Lemsi MC, David N, Sahb Rd; les participants de la table ronde n°6 de Giens XXIII. Jeunne CL, et al. Therapie. 2008 Mar-Apr;63(2):107-11. doi: 10.2515/therapie:2008020. Therapie. 2008. PMID: 27393728 French. No abstract available.
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
Zannad F, De Backer G, Graham I, Lorenz M, Mancia G, Morrow DA, Reiner Z, Koenig W, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L; ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Zannad F, et al. Fundam Clin Pharmacol. 2012 Apr;26(2):163-74. doi: 10.1111/j.1472-8206.2011.01023.x. Epub 2012 Jan 5. Fundam Clin Pharmacol. 2012. PMID: 22220636 Review.
64 results